FindTrial
Sign In

Late phase II study on dose response of SMP-508 monotherapy in patients with type 2 diabetes mellitus

Late phase II study on dose response of SMP-508 monotherapy in patients with type 2 diabetes mellitus

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220179
Enrollment
Unknown
Registered
2005-11-25
Start date
2005-11-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus patients whose blood glucose levels are not adequately controlled by diet and exercise therapies

Interventions

investigational material(s) Generic name etc : SMP-508 (repaglinide) INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigationa

Sponsors

Dainippon Sumitomo Pharma Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus who satisfy the following inclusion criteria -Patients who are undergoing only diet and exercise therapies -Patients whose HbA1c levels are 6.5% -Patients with hepatic dysfunction -Patients with renal dysfunction -Patients with cardiac diseases or severe hypertension etc.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy: postprandial blood glucose, HbA1c etc—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026